相关实验视频
Updated: Jul 20, 2025

08:51
A New Murine Model of Endovascular Aortic Aneurysm Repair
Published on: July 7, 2013
14.4K
血清蛋白质识别和验证两种新的动脉硬化大动脉动脉瘤生物标志物,profilin 1和补充因子D的血清蛋白质识别和验证
Yusuke Murakami1,2, Mitsuhiro Nishigori2,3,4, Hiroaki Yagi3,5
1Fundamental Research Laboratory, Research and Development Division, Eiken Chemical Co., Ltd., 143 Nogi, Nogimachi, Shimotsuga-gun, Tochigi, 329-0114, Japan.
Proteome science
|August 5, 2023
概括
新的血液生物标志物,Profilin 1 (PFN1) 和补充因子D (CFD),显示出对诊断大动脉动脉瘤 (AA) 的希望. 它们的联合使用可以提高胸腔和腹部大动脉动脉瘤的诊断准确度.
科学领域:
- 生物化学 生物化学
- 蛋白质组学是指蛋白质组学.
- 心血管医学 心血管医学
背景情况:
- 大动脉动脉瘤 (AA) 诊断缺乏可靠的血液生物标志物,阻碍了早期检测和风险评估.
- 目前的AA生物标志物缺乏特异性和临床可靠性.
研究的目的:
- 确定新型的,血液检测到的大动脉动脉瘤 (AA) 的诊断生物标志物.
- 评估胸部AA (TAA) 和腹部AA (AAA) 的已识别的生物标志物的诊断性能.
主要方法:
- 来自TAA患者和健康对照 (HC) 的血清样本的蛋白质组分析.
- 主要蛋白质的耗尽和脂蛋白分量的分析.
- 在所有分数中均改变的生物标志物的识别.
- 使用接收器操作特征 (ROC) 分析和临床样本进行验证.
主要成果:
- 鉴定出1型蛋白 (PFN1) 和补充因子D (CFD) 是有前途的生物标志物候选物.
- 与HC相比,TAA和AAA患者的PFN1水平下降,而CFD水平增加.
- ROC分析表明,PFN1和CFD有能力将AA患者与对照患者区分开来.
- 结合PFN1和CFD改善了诊断性能 (AUC).
- 在患有大动脉解剖的患者中观察到显著的差异.
结论:
- PFN1和CFD是TAA和AAA的潜在基于血液的诊断生物标志物.
- 结合PFN1和CFD可以提高它们的诊断效用.
- 这些生物标志物可能有助于开发AA的诊断系统.
相关概念视频
Aneurysm II: Clinical Manifestations and Diagnostic Studies
10
Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
10
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
119
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
119
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
13
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
13
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
201
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
201

